Clinical trials: Cholangiocarcinomas
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Gastrointestinal Cancer, Colorectal Cancer
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer
- Trial name
- NCT04077372
- Testing
- Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Pancreas Cancer, Bile Duct Cancer
Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy
Pancreaticoduodenectomy is associated with a high incidence of postoperative complications. These postoperative complications could delay postoperative resumption of adequate oral intake.
- Conditions
- Pancreas Cancer, Bile Duct Cancer, Ampulla of Vater Cancer
- Trial name
- NCT00809081
- Testing
- Enteral Feeding and Total Parental Support
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Yonsei University
Bile Duct Cancer
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
Bile duct tumours are rare. They are the 6th most common type of digestive cancer. Their therapeutic management is complex and must be multidisciplinary in nature.
- Trial name
- AMEBICA (NCT02591030)
- Testing
- GEMCIS, mFolfirinox
- Where
- 42 sites in France
- Volunteers
- 191 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Cholangiocarcinoma
Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
Investigation of the effects of daily sildenafil on patients with pancreatic or cholangiocarcinoma cancer undergoing treatment.
- Trial name
- PCC (NCT02106871)
- Testing
- Sildenafil
- Where
- United States
- Sponsor
- The University of Texas Medical Branch, Galveston
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Primary Sclerosing Cholangitis (PSC)
Endoscopy and Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a chronic, cholestatic, immune-mediated liver disease characterized by segmental inflammation, fibrosis and destruction of the intra and / or extrahepatic biliary tree.
- Trial name
- NCT06686810
- Testing
- Endoscopic Retrogradade CholangioPancreatography (ERCP)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Intrahepatic Cholangiocarcinoma
Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
This study will evaluate the efficacy and safety of cryoablation combined with SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, plus famitinib, a multi-targeted receptor tyrosine kinase inhibitor, in patients…
- Trial name
- CASTLE-ZS-03 (NCT07147088)
- Testing
- SHR-1701, Famitinib, Cryoablation
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fudan University
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bile Duct Stricture, Cholangiocarcinoma
Diagnosis of Bile Duct Strictures
The purpose of this prospective study is to compare the diagnostic utility of two techniques (brush cytology + FISH and brush cytology + free DNA analysis) in the diagnosis of biliary strictures.
- Conditions
- Bile Duct Stricture, Cholangiocarcinoma, Pancreatic Cancer, Chronic Pancreatitis
- Trial name
- NCT02000999
- Testing
- brushing of bile duct strictures for cytology
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Washington University School of Medicine
Cholangiocarcinoma, Urothelial Cancer
A Study of TAS-120 in Patients With Advanced Solid Tumors
This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120).
- Conditions
- Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors
- Trial name
- NCT02052778
- Testing
- Futibatinib
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 407 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
This study looks at better ways to measure how tumors respond to treatment before surgery. Today, doctors often use RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), which measures the longest diameter across a tumor on…
- Conditions
- Breast Cancer, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma), Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
- Trial name
- NCT07319767
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Hepatocellular Carcinoma, Cholangiocarcinoma
Open Versus Laparoscopic Ablation of Liver Malignancies
The purpose of this study is to compare laparoscopic ablation to open ablation of liver malignancies regarding complication rates and ablation response as well as quality of life following the surgery.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- OPTIMAL (NCT06304766)
- Testing
- Laparoscopic ablation, Open ablation
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Hilar Cholangiocarcinoma, Biliary Obstruction
Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma
The study aim to evaluate the efficacy of intraductal radiofrequency ablation for unresetable hilar cholangiocarcinoma in addition to biliary stenting.
- Trial name
- NCT04611100
- Testing
- ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)
- Where
- Thailand
- Volunteers
- 70 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Bile Duct Cancer, Chemotherapy Effect
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
To assess the effect of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients who have failed to 1st-line chemotherapy.
- Trial name
- NCT04298021
- Testing
- AZD6738, Durvalumab, Olaparib
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.